# Human mAbs, bacterial diseases in humans.# Target identification.# Freedom-to-operate projects.# Patenting and IP.# Antigen production and quality control, for mAb discovery.# mAb discovery, production, preclinicaal screening.# mAb engineering.# Patenting and IP.# Project design and management (interal, external academics, external industrial, government grants)..

# Technology development, bacterial display. # Discovery of protein vaccine antigens, across Intercell portfolio (human pathogens).# Recombinant protein production for preclinical studies and mAb development, incl labelling of proteins.# Molecular microbiology project support, across portfolio.# Project management (eg large EU-funded projects).# Leader for Intercell's human monoclonal antibody programme.# Due dilligence in technology acquisition situations.# Patent and IP responsible.

# Toxicity biomarker discovery, across NN portfolio.# Evaluation of toxicity mechanisms in preclinical animal models.# Evaluation of carcinogenicity mechanisms in preclinical animal models.# Development of mammalian cell-based in vitro toxicity assays, across NN portfolio.# GLP accreditation of mammalian cell-based in vitro toxicity assays, across NN portfolio.# Development and implementation of novel molecular toxicology techniques.# Preclinical flow cytometry and sorting facility.# Research project initiation and management with academical and industrial partners.

# Molecular toxicology technology development.# Mode-of-action molecular toxicology studies.

Freedom-to-operate technology development in the area of human monoclonal antibodies.

# Development of molceular and serology diagnostics, veterinary virology.# Design and execution of biotechnology/virology research projects.# Endemic as well as notifiable viral diseases.